Overview

Study to Evaluate the 2-Way Interaction Between Multiple Doses of Epanova™ and a Single Dose of Rosuvastatin (Crestor®)

Status:
Completed
Trial end date:
2013-11-01
Target enrollment:
Participant gender:
Summary
This study is intended to evaluate the potential 2-way reciprocal interaction between multiple doses of Epanova™ and a single dose of rosuvastatin
Phase:
Phase 1
Details
Lead Sponsor:
AstraZeneca
Treatments:
Eicosapentaenoic acid ethyl ester
Rosuvastatin Calcium